{"id":"https://openalex.org/W3010441993","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.8539","title":"A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma","display_name":"A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma","publication_year":2007,"publication_date":"2007-06-20","ids":{"openalex":"https://openalex.org/W3010441993","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.8539","mag":"3010441993"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2007.25.18_suppl.8539","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.8539","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2007.25.18_suppl.8539","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113557903","display_name":"Kenneth Wyman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Wyman","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018054038","display_name":"David Robert Spigel","orcid":"https://orcid.org/0000-0003-3215-9465","observed_orcids":["https://orcid.org/0000-0003-3215-9465"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Spigel","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049243227","display_name":"Igor J. Puzanov","orcid":"https://orcid.org/0000-0002-9803-3497","observed_orcids":["https://orcid.org/0000-0002-9803-3497"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. Puzanov","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065917441","display_name":"John Daniel Hainsworth","orcid":"https://orcid.org/0000-0002-2848-6546","observed_orcids":["https://orcid.org/0000-0002-2848-6546"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Hainsworth","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023047936","display_name":"Mark C. Kelley","orcid":"https://orcid.org/0000-0002-5188-1931","observed_orcids":["https://orcid.org/0000-0002-5188-1931"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Kelley","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072065263","display_name":"Peggy Krozely","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Krozely","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002578603","display_name":"Duveen Sturgeon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Sturgeon","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I901861585"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075566772","display_name":"Jeffrey Alan Sosman","orcid":"https://orcid.org/0000-0002-0650-9698","observed_orcids":["https://orcid.org/0000-0002-0650-9698"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Sosman","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN; Sarah Cannon Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I901861585"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"25","issue":"18_suppl","first_page":"8539","last_page":"8539"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.5576000213623047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.5576000213623047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.3555000126361847,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0406000018119812,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9509999752044678},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/egfr-inhibition","display_name":"EGFR inhibition","score":0.765999972820282},{"id":"https://openalex.org/keywords/vegf-inhibition","display_name":"VEGF inhibition","score":0.9710000157356262},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8299999833106995},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7699999809265137},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.5270000100135803},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.6019999980926514},{"id":"https://openalex.org/keywords/intestinal-perforation","display_name":"intestinal perforation","score":0.9679999947547913},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.421999990940094},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.4300000071525574},{"id":"https://openalex.org/keywords/central-nervous-system-metastases","display_name":"central nervous system metastasis","score":0.5239999890327454},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.3199999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9503111243247986},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.9001327753067017},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.788110077381134},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7292867302894592},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6759923100471497},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5626503229141235},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.42894643545150757},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4211616516113281},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4131612479686737},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3599231243133545},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3455246388912201},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3372732400894165},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2677737772464752},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.20453548431396484},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.13720101118087769},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.06080940365791321}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2007.25.18_suppl.8539","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.8539","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2007.25.18_suppl.8539","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2150349343","https://openalex.org/W2245230423","https://openalex.org/W2137721949","https://openalex.org/W1998193510","https://openalex.org/W2056976042","https://openalex.org/W2244050546","https://openalex.org/W2280647462","https://openalex.org/W4249382411","https://openalex.org/W2115369775","https://openalex.org/W2898202033"],"abstract_inverted_index":{"8539":[0],"Background:":[1],"Erlotinib":[2],"and":[3,36,47,74,81,89,112,124,173,193,208,227,276,287,304],"bevacizumab":[4,48,90,305],"have":[5],"demonstrated":[6],"activity":[7],"in":[8,22,49,311],"a":[9,40,175,197,322],"number":[10],"of":[11,15,34,114,148,160,185,242,256,300,321,324],"malignancies":[12],"by":[13],"virtue":[14],"interrupting":[16],"interdependent":[17],"signaling":[18],"pathways":[19],"thought":[20,291],"important":[21],"tumorigenesis.":[23],"Melanoma":[24],"may":[25],"be":[26,293,328],"an":[27],"appropriate":[28],"target":[29],"based":[30],"on":[31],"its":[32],"expression":[33],"EGFR":[35],"VEGF.":[37],"We":[38],"conducted":[39],"phase":[41],"II":[42],"multi-institutional":[43],"trial":[44],"evaluating":[45],"erlotinib":[46,86,301],"advanced":[50],"melanoma":[51,155,315],"patients.":[52],"Methods:":[53],"Eligibility":[54],"included":[55,120],"measurable":[56],"disease,":[57,73],"ECOG":[58],"PS":[59,198],"=":[60,134,178,199],"0\u20131,":[61],"adequate":[62],"organ":[63],"function,":[64],"no":[65],"more":[66],"than":[67],"one":[68],"prior":[69,205,212],"therapy":[70,207,213],"for":[71,165,214],"metastatic":[72,154,215,314],"CNS":[75],"metastases":[76],"were":[77,106,144,156,163,218,261,283],"allowed":[78],"if":[79],"limited":[80],"controlled.":[82],"Patients":[83],"received":[84],"oral":[85],"150":[87],"mg/day":[88],"10":[91],"mg/kg":[92],"IV":[93,281],"Q":[94],"2":[95],"weeks":[96],"with":[97,153,263,313,316],"tumor":[98],"evaluation":[99],"every":[100],"8":[101],"weeks.":[102],"The":[103,167,237,298],"primary":[104],"outcomes":[105,119],"response":[107,110],"rate":[108],"(RR),":[109],"duration,":[111],"frequency":[113],"PFS":[115,138],">6":[116,139],"months.":[117,236],"Secondary":[118],"overall":[121],"survival,":[122],"safety,":[123],"tolerability.":[125],"A":[126,158,254],"two-stage":[127],"accrual":[128],"design":[129],"was":[130,169,245],"employed":[131],"ensuring":[132],"that":[133],"3/21":[135],"patients":[136,143,152,162,202,210,244,312,326],"had":[137,174,188,196,204,230],"months":[140,226],"before":[141],"additional":[142],"accrued.":[145],"Results:":[146],"As":[147],"Nov":[149],"2006,":[150],"29":[151,187],"enrolled.":[157],"total":[159,255,323],"23":[161],"evaluable":[164,243],"response.":[166],"majority":[168],"male":[170],"19/29":[171],"(65%)":[172],"median":[176,238],"age":[177],"62":[179],"yrs":[180],"(range":[181],"35\u201378":[182],"years).":[183],"Fifteen":[184],"the":[186,264],"stage":[189],"M1c":[190],"disease":[191,232],"(51.7%)":[192],"18/29":[194],"(62.1%)":[195],"1.":[200],"Ten":[201],"(34%)":[203],"adjuvant":[206],"6":[209,225,235],"(21%)":[211],"disease.":[216],"There":[217],"2/23":[219],"(9%)":[220],"partial":[221],"responses":[222],"lasting":[223,233],"<":[224],"5/23":[228],"(22%)":[229],"stable":[231],">":[234],"progression":[239],"free":[240],"survival":[241],"96":[246],"days":[247],"(95%":[248],"CI:":[249],"50":[250],"-":[251],"142":[252],"days).":[253],"25":[257],"grade":[258,280],"III":[259],"toxicities":[260,282],"observed":[262,284],"most":[265],"common":[266],"being":[267],"rash/pruritis":[268],"(n=4),":[269,271],"pain":[270],"fatigue":[272],"(n=3),":[273],"hypertension":[274],"(n=2)":[275],"diarrhea":[277],"(n=2).":[278],"Two":[279],"(myocardial":[285],"infarction":[286],"bowel":[288],"perforation)":[289],"both":[290],"to":[292,295],"due":[294],"bevacizumab.":[296],"Conclusion:":[297],"combination":[299],"(150":[302],"mg/day)":[303],"(10":[306],"mg/kg)":[307],"appears":[308],"potentially":[309],"active":[310],"largely":[317],"tolerable":[318],"toxicities.":[319],"Accrual":[320],"41":[325],"will":[327],"completed":[329],"shortly.":[330],"[Table:":[331],"see":[332],"text]":[333]},"counts_by_year":[{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-10T09:11:00.788812","created_date":"2020-03-13T00:00:00"}